INS and Hypoglycemia: Synthetic SGLT2 inhibitors lower glucose primarily through promoting glucosuria, and in this way, these molecules are effective at lowering plasma glucose concentrations without inducing hypoglycemia because they act independently of the need for the pancreas to secrete or respond to insulin [75].